Development of a High Throughput Cell-Based Assay for Soluble Epoxide Hydrolase Using BacMam Technology
详细信息 查看全文
- 作者：Wensheng Xie (1)
Xiaoyan Tang (1)
Quinn Lu (1)
Robert S. Ames (1)
Steven J. Ratcliffe (2)
Hu Li (1) - 关键词：Soluble epoxide hydrolase (sEH) ; Cell ; based assay ; BacMam technology ; Fluorescence polarization (FP) ; High throughput
- 刊名：Molecular Biotechnology
- 出版年：2010
- 出版时间：July 2010
- 年：2010
- 卷：45
- 期：3
- 页码：207-217
- 全文大小：531KB
- 参考文献：1. Campbell, W. B., Brady, M. T., Rosolowsky, L. J., & Falck, J. R. (1991). Metabolism of arachidonic acid by rat adrenal glomerulosa cells: Synthesis of hydroxyeicosatetraenoic acids and epoxyeicosatrienoic acids. / Endocrinology, / 128, 2183鈥?194. CrossRef
2. Spector, A. A. (2009). Arachidonic acid cytochrome P450 epoxygenase pathway. / Journal of Lipid Research, / 50(Suppl), S52鈥揝56. CrossRef
3. Spector, A. A., & Norris, A. W. (2007). Action of epoxyeicosatrienoic acids on cellular function. / American Journal of Physiology Cell Physiology, / 292, C996鈥揅1012. CrossRef
4. Fisslthaler, B., Popp, R., Kiss, L., Potente, M., Harder, D. R., Fleming, I., et al. (1999). Cytochrome P450 2C is an EDHF synthase in coronary arteries. / Nature, / 401, 493鈥?97. CrossRef
5. Gauthier, K. M., Yang, W., Gross, G. J., & Campbell, W. B. (2007). Roles of epoxyeicosatrienoic acids in vascular regulation and cardiac preconditioning. / Journal of Cardiovascular Pharmacology, / 50, 601鈥?08. CrossRef
6. Larsen, B. T., Gutterman, D. D., & Hatoum, O. A. (2006). Emerging role of epoxyeicosatrienoic acids in coronary vascular function. / European Journal of Clinical Investigation, / 36, 293鈥?00. CrossRef
7. Fleming, I. (2007). Epoxyeicosatrienoic acids, cell signaling and angiogenesis. / Prostaglandins & Other Lipid Mediators, / 82, 60鈥?7. CrossRef
8. Batchu, S. N., Law, E., Brocks, D. R., Falck, J. R., & Seubert, J. M. (2009). Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. / Journal of Molecular and Cellular Cardiology, / 46, 67鈥?4. CrossRef
9. Proctor, K. G., Falck, J. R., & Capdevila, J. (1987). Intestinal vasodilation by epoxyeicosatrienoic acids: Arachidonic acid metabolites produced by a cytochrome P450 monooxygenase. / Circulation Research, / 60, 50鈥?9.
10. Weintraub, N. L., Fang, X., Kaduce, T. L., VanRollins, M., Chatterjee, P., & Spector, A. A. (1997). Potentiation of endothelium-dependent relaxation by epoxyeicosatrienoic acids. / Circulation Research, / 81, 258鈥?67.
11. Yang, W., Holmes, B. B., Gopal, V. R., Kishore, R. V., Sangras, B., Yi, X. Y., et al. (2007). Characterization of 14, 15-epoxyeicosatrienoyl-sulfonamides as 14, 15-epoxyeicosatrienoic acid agonists: Use for studies of metabolism and ligand binding. / The Journal of pharmacology and experimental therapeutics, / 321, 1023鈥?031. CrossRef
12. Lu, T., Ye, D., Wang, X., Seubert, J. M., Graves, J. P., Bradbury, J. A., et al. (2006). Cardiac and vascular KATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms. / The Journal of Physiology, / 575, 627鈥?44. CrossRef
13. Zou, A. P., Fleming, J. T., Falck, J. R., Jacobs, E. R., Gebremedhin, D., Harder, D. R., et al. (1996). Stereospecific effects of epoxyeicosatrienoic acids on renal vascular tone and K(+)-channel activity. / The American Journal of Physiology, / 270, F822鈥揊832.
14. Li, P. L., & Campbell, W. B. (1997). Epoxyeicosatrienoic acids activate K+ channels in coronary smooth muscle through a guanine nucleotide binding protein. / Circulation Research, / 80, 877鈥?84.
15. Yang, W., Tuniki, V. R., Anjaiah, S., Falck, J. R., Hillard, C. J., & Campbell, W. B. (2008). Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20-125i-14,15-epoxyeicosa-8(Z)-enoic acid. / The Journal of Pharmacology and Experimental Therapeutics, / 324, 1019鈥?027. CrossRef
16. Shi, Y., Liu, X., Gebremedhin, D., Falck, J. R., Harder, D. R., & Koehler, R. C. (2008). Interaction of mechanisms involving epoxyeicosatrienoic acids, adenosine receptors, and metabotropic glutamate receptors in neurovascular coupling in rat whisker barrel cortex. / Journal of Cerebral Blood Flow and Metabolism, / 28, 111鈥?25. CrossRef
17. Behm, D. J., Ogbonna, A., Wu, C., Burns-Kurtis, C. L., & Douglas, S. A. (2009). Epoxyeicosatrienoic acids function as selective, endogenous antagonists of native thromboxane receptors: Identification of a novel mechanism of vasodilation. / The Journal of Pharmacology and Experimental Therapeutics, / 328, 231鈥?39. CrossRef
18. Chen, J. K., Capdevila, J., & Harris, R. C. (2001). Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis. / Molecular and Cellular Biology, / 21, 6322鈥?331. CrossRef
19. Yang, S., Lin, L., Chen, J. X., Lee, C. R., Seubert, J. M., Wang, Y., et al. (2007). Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways. / American Journal of Physiology, / 293, H142鈥揌151. CrossRef
20. Beetham, J. K., Tian, T., & Hammock, B. D. (1993). cDNA cloning and expression of a soluble epoxide hydrolase from human liver. / Archives of Biochemistry and Biophysics, / 305, 197鈥?01. CrossRef
21. Newman, J. W., Morisseau, C., & Hammock, B. D. (2005). Epoxide hydrolases: Their roles and interactions with lipid metabolism. / Progress in Lipid Research, / 44, 1鈥?1. CrossRef
22. Pacifici, G. M., Temellini, A., Giuliani, L., Rane, A., Thomas, H., & Oesch, F. (1988). Cytosolic epoxide hydrolase in humans: Development and tissue distribution. / Archives of Toxicology, / 62, 254鈥?57. CrossRef
23. Enayetallah, A. E., French, R. A., Thibodeau, M. S., & Grant, D. F. (2004). Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. / Journal of Histochemistry and Cytochemistry, / 52, 447鈥?54.
24. Chiamvimonvat, N., Ho, C. M., Tsai, H. J., & Hammock, B. D. (2007). The soluble epoxide hydrolase as a pharmaceutical target for hypertension. / Journal of Cardiovascular Pharmacology, / 50, 225鈥?37. CrossRef
25. Inceoglu, B., Schmelzer, K. R., Morisseau, C., Jinks, S. L., & Hammock, B. D. (2007). Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). / Prostaglandins & Other Lipid Mediators, / 82, 42鈥?9. CrossRef
26. Zhang, W., Koerner, I. P., Noppens, R., Grafe, M., Tsai, H. J., Morisseau, C., et al. (2007). Soluble epoxide hydrolase: A novel therapeutic target in stroke. / Journal of Cerebral Blood Flow and Metabolism, / 27, 1931鈥?940. CrossRef
27. Sinal, C. J., Miyata, M., Tohkin, M., Nagata, K., Bend, J. R., & Gonzalez, F. J. (2000). Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. / The Journal of Biological Chemistry, / 275, 40504鈥?0510. CrossRef
28. Zhang, W., Otsuka, T., Sugo, N., Ardeshiri, A., Alhadid, Y. K., Iliff, J. J., et al. (2008). Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. / Stroke; A Journal of Cerebral Circulation, / 39, 2073鈥?078.
29. Corenblum, M. J., Wise, V. E., Georgi, K., Hammock, B. D., Doris, P. A., & Fornage, M. (2008). Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat. / Hypertension, / 51, 567鈥?73. CrossRef
30. Fornage, M., Hinojos, C. A., Nurowska, B. W., Boerwinkle, E., Hammock, B. D., Morisseau, C. H., et al. (2002). Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. / Hypertension, / 40, 485鈥?90. CrossRef
31. Morisseau, C., Goodrow, M. H., Dowdy, D., Zheng, J., Greene, J. F., Sanborn, J. R., et al. (1999). Potent urea and carbamate inhibitors of soluble epoxide hydrolases. / Proceedings of the National Academy of Sciences of the United States of America, / 96, 8849鈥?854. CrossRef
32. Morisseau, C., Goodrow, M. H., Newman, J. W., Wheelock, C. E., Dowdy, D. L., & Hammock, B. D. (2002). Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. / Biochemical Pharmacology, / 63, 1599鈥?608. CrossRef
33. McElroy, N. R., Jurs, P. C., Morisseau, C., & Hammock, B. D. (2003). QSAR and classification of murine and human soluble epoxide hydrolase inhibition by urea-like compounds. / Journal of Medicinal Chemistry, / 46, 1066鈥?080. CrossRef
34. Li, J., Carroll, M. A., Chander, P. N., Falck, J. R., Sangras, B., & Stier, C. T. (2008). Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. / Frontiers in Bioscience, / 13, 3480鈥?487. CrossRef
35. Olearczyk, J. J., Quigley, J. E., Mitchell, B. C., Yamamoto, T., Kim, I. H., Newman, J. W., et al. (2009). Administration of a substituted adamantly-urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. / Clinical Science (Lond), 116, 61鈥?0. CrossRef
36. Imig, J. D., Zhao, X., Capdevila, J. H., Morisseau, C., & Hammock, B. D. (2002). Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. / Hypertension, / 39, 690鈥?94. CrossRef
37. Zhao, X., Yamamoto, T., Newman, J. W., Kim, I. H., Watanabe, T., Hammock, B. D., et al. (2004). Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. / Journal of the American Society of Nephrology, / 15, 1244鈥?253.
38. Smith, K. R., Pinkerton, K. E., Watanabe, T., Pedersen, T. L., Ma, S. J., & Hammock, B. D. (2005). Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. / Proceedings of the National Academy of Sciences of the United States of America, / 102, 2186鈥?191. CrossRef
39. Ghosh, S., Chiang, P. C., Wahlstrom, J. L., Fujiwara, H., Selbo, J. G., & Roberds, S. L. (2008). Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. / Basic & Clinical Pharmacology & Toxicology, / 102, 453鈥?58. CrossRef
40. Nithipatikom, K., Falck, J. R., Bhatt, R. K., Hanke, C. J., & Campbell, W. B. (1997). Determination of 14,15-epoxyeicosatrienoic acid and 14,15-dihydroxyeicosatrienoic acid by fluoroimmunoassay. / Analytical Biochemistry, / 246, 253鈥?59. CrossRef
41. Wolf, N. M., Morisseau, C., Jones, P. D., Hock, B., & Hammock, B. D. (2006). Development of a high-throughput screen for soluble epoxide hydrolase inhibition. / Analytical Biochemistry, / 355, 71鈥?0. CrossRef
42. Jones, P. D., Wolf, N. M., Morisseau, C., Whetstone, P., Hock, B., & Hammock, B. D. (2005). Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. / Analytical Biochemistry, / 343, 66鈥?5. CrossRef
43. Owicki, J. C. (2000). Fluorescence polarization and anisotropy in high throughput screening: Perspectives and primer. / Journal of Biomolecular Screening, / 5, 297鈥?06. CrossRef
44. Luckow, V. A., Lee, S. C., Barry, G. F., & Olins, P. O. (1993). Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in / Escherichia coli. / Journal of Virology, / 67, 4566鈥?579.
45. Fornwald, J. A., Lu, Q., Wang, D., & Ames, R. S. (2007). Gene expression in mammalian cells using BacMam, a modified baculovirus system. / Methods in Molecular Biology, / 388, 95鈥?14. CrossRef
46. Kost, T. A., Condreay, J. P., Ames, R. S., Rees, S., & Romanos, M. A. (2007). Implementation of BacMam virus gene delivery technology in a drug discovery setting. / Drug discovery today, / 12, 396鈥?03. CrossRef
47. Ames, R. S., Kost, T. A., & Condreay, J. P. (2007). BacMam technology and its application to drug discovery. / Expert Opinion on Drug Discovery, / 2, 1669鈥?681. CrossRef
48. Condreay, J. P., Ames, R. S., Hassan, N. J., Kost, T. A., Merrihew, R. V., Mossakowska, D. E., et al. (2006). Baculoviruses and mammalian cell-based assays for drug screening. / Advances in Virus Research, / 68, 255鈥?86. CrossRef
49. Yang, J., Copeland, R. A., & Lai, Z. (2009). Defining balanced conditions for inhibitor screening assays that target bisubstrate enzymes. / Journal of Biomolecular Screening, / 14, 111鈥?20. CrossRef
50. Macarron, R., & Hertzberg, R. P. (2002). Design and implementation of high throughput screening assays. / Methods in Molecular Biology, / 190, 1鈥?9.
51. Zhang, J. H., Chung, T. D., & Oldenburg, K. R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. / Journal of Biomolecular Screening, / 4, 67鈥?3. CrossRef
52. Kerr, B. M., Rettie, A. E., Eddy, A. C., Loiseau, P., Guyot, M., Wilensky, A. J., et al. (1989). Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: In vitro/in vivo correlation. / Clinical Pharmacology and Therapeutics, / 46, 82鈥?3. - 作者单位：Wensheng Xie (1)
Xiaoyan Tang (1)
Quinn Lu (1)
Robert S. Ames (1)
Steven J. Ratcliffe (2)
Hu Li (1)
1. Biological Reagents and Assay Development, Molecular Discovery Research, GlaxoSmithKline, 1250 S. Collegeville Road, Collegeville, PA, 19426, USA
2. Computational and Structural Chemistry, Molecular Discovery Research, GlaxoSmithKline, Harlow NFSP, Third Avenue, Essex, CM19 5AW, UK
文摘